Prime Highlights: 

• Glenmark Pharma’s Q2 profit jumped 72.2%, boosting investor confidence and lifting the stock during early trade. 

• The company recorded major revenue from its licensing deal with AbbVie for its investigational drug ISB 2001, supporting overall quarterly growth. 

Key Facts: 

• Glenmark reported a profit after tax of ₹610.43 crore, up from ₹354.49 crore in the same quarter last year. 

• Consolidated revenue rose to ₹6,046.87 crore, driven largely by the $525 million booked from the AbbVie agreement. 

Background: 

Glenmark Pharmaceuticals witnessed a strong start to the week as its shares climbed after the company posted an impressive 72.2% jump in profit for the September 2025 quarter. The stock rose as much as 1.5% to ₹1,924.9 during intraday trade, marking its biggest single-session gain since mid-November. It later settled slightly lower but still traded nearly 1% higher at ₹1,913, outperforming the Nifty 50, which was up 0.22% around the same time. 

The rally comes as Glenmark continues its positive market momentum, with the stock advancing for the fourth straight session and currently trading at nearly 25 times its 30-day average volume. So far this year, the counter has gained 19%, outpacing the benchmark index’s 9.8% rise. The company now holds a market capitalisation of ₹53,968 crore. 

Glenmark reported a profit after tax of ₹610.43 crore for Q2 FY26, up sharply from ₹354.49 crore a year earlier. The strong performance came mainly from the revenue Glenmark booked through its licensing deal with AbbVie for its experimental drug ISB 2001. The company booked $525 million from the deal during the quarter, part of the larger $1.925 billion agreement. 

Total consolidated revenue rose to ₹6,046.87 crore, compared with ₹3,433.8 crore in the same quarter last year. While India formulation sales declined due to inventory adjustments and GST-related logistics issues, Glenmark’s North America business recorded a substantial jump, with sales rising to ₹4,465.6 crore from ₹740.5 crore in the previous year. 

Chairman and Managing Director Glenn Saldanha said the partnership with AbbVie strengthens the company’s scientific foundation and supports future pipeline development. Brokerages expect further traction as Glenmark aims for additional European approvals for Winlevi and plans a commercial rollout across licensed EU markets by the end of FY26.